UK co-ordinating investigator international clinical trial: A Phase 2 Study to Assess the Efficacy and Safety of CAL-101 in Patients with Indolent B-Cell Non-Hodgkin Lymphoma Refractory to Rituximab and Alkylating Agents

Activity: Internal positions, career professional development and otherOtherResearch

PeriodSept 2010Oct 2013
Held atGilead Sciences Europe Ltd, United Kingdom
Degree of RecognitionInternational